Sentences with phrase «by myeloma»

These diseases include neurodegenerative conditions, such as Alzheimer's disease (AD), Parkinson's disease (PD), tauopathies, prion protein diseases, as well as peripheral amyloidoses, such as immunoglobulin light chain amyloidosis caused by myeloma.

The monoclonal protein produced by the myeloma cells interferes with normal blood cell production.

Not exact matches

And that, of course, was a very different reason from the one that had brought him and his fellow lunch mates to gather that afternoon — at a day of scientific panels and presentations sponsored by the Multiple Myeloma Research Foundation.

Celgene loses patent protection by 2022 for Revlimid, its top - selling multiple myeloma drug that brought in about 60 percent of fiscal third quarter revenue of nearly $ 3.3 billion.

THE PATIENT AS INNOVATOR With Deborah Brooks of The Michael J. Fox Foundation for Parkinson's Research; Kathy Giusti of the Multiple Myeloma Research Foundation & Consortium; Sean Lane of Crosschx; Claudia Williams of the White House Office of Science and Technology Policy; Rik Kirkland, of McKinsey & Co. — Report by Kia Kokalitcheva — Video: Patients Should Get Access to Their Health Data

Forbes profiles founder, Kathy Giusti, highlighting her own personal journey and the extraordinary results made possible by the MMRF and the entire myeloma community.

Multiple myeloma drug Revlimid and anti-inflammatory Otezla have the potential to grow sales by double - digits throughout the remainder of the decade while also expanding into a number of new indications.

So far, its trials have shown it can improve outcomes when used alongside other multiple myeloma drugs and that could offer it some insulation if the market gets disrupted by new treatment approaches, such as gene therapy.

Researchers used tissue and blood samples to show that the gammopathy (a precursor to myeloma) in both mice and patients with Gaucher disease is triggered by specific lipids, and that the antibodies made by tumor cells in nearly a third of myeloma patients are directed against such lipids.

Senior author Madhav Dhodapkar, M.D., the Arthur H. and Isabel Bunker Professor of Medicine and Immunobiology, and chief of Hematology, said the study, using tissue and blood samples from humans and mice, shows that chronic stimulation of the immune system by lipids made in the context of inflammation underlies the origins of at least a third of all myeloma cases.

Of 32 patients participating in the trial, 11 had a partial response to the drug regimen, meaning a decrease in the extent of the cancer, and 53 had a very good partial response, meaning the level of certain myeloma - related proteins in the blood declines by more than 90 percent.

Focusing on adiponectin led Dr. Medina's lab to protein kinase A or «PKA» — a protein that, when activated by adiponectin, suppresses the fatty acids that myeloma cells need, leading to their demise.

«This new mechanism of Runx2 overexpression can give multiple myeloma cells a bone cell - like phenotype,» Yang said of the work by her lab and collaborators.

Multiple myeloma is preceded by a blood disorder called monoclonal gammopathy of undetermined significance (MGUS) in which abnormal plasma cells produce many copies of an antibody protein.

«For patients diagnosed with MGUS, maintaining a healthy weight may be a way to prevent the progression to multiple myeloma, if further confirmed by clinical trials.»

«We are excited by the work of Dr. Pourdehnad and colleagues and believe these results are an important advance in understanding the role of myc pathway dysregulation in multiple myeloma, and ultimately allow for the development of therapeutic strategies to address it,» said Jeffrey Wolf, MD, a UCSF blood disorder specialist and director of the Stephen and Nancy Grand Multiple Myeloma Translational Initiative at UCSF, a sponsor of the remyeloma, and ultimately allow for the development of therapeutic strategies to address it,» said Jeffrey Wolf, MD, a UCSF blood disorder specialist and director of the Stephen and Nancy Grand Multiple Myeloma Translational Initiative at UCSF, a sponsor of the reMyeloma Translational Initiative at UCSF, a sponsor of the research.

A randomized phase III trial finding that a new monoclonal antibody, elotuzumab, added to standard therapy, extended the duration of remission for patients with relapsed multiple myeloma by about five months Findings from two phase III studies showing that children with Wilms tumor who have a specific chromosomal abnormality do better with a more intensive, augmented chemotherapy regimen

A new study published online by JAMA Oncology examines the assessment of minimal residual disease in patients newly treated for multiple myeloma as a factor in survival outcomes.

Using an approach developed at Maisonneuve - Rosemont, consisting of an autograft to reduce tumour mass followed by a family allograft three to four months later to clean the bone marrow of myeloma cells with immune cells from a family donor (immunotherapy), the study resulted in a total cure rate of 41 %, a record level using this strategy.

Patients with multiple myeloma (MM) appear to have better survival if they are found to have monoclonal gammopathy of undetermined significance (MGUS) first, the state that precedes MM and which is typically diagnosed as part of a medical workup for another reason, according to a study published online by JAMA Oncology.

A new therapeutic approach tested by a team from Maisonneuve - Rosemont Hospital (CIUSSS - EST, Montreal) and the University of Montreal gives promising results for the treatment of multiple myeloma, a cancer of the bone marrow currently considered incurable with conventional chemotherapy and for which the average life expectancy is about 6 or 7 years.

The study follows similar investigations by Garland and colleagues of other cancers, including breast, colon, pancreas, bladder and multiple myeloma.

A study that used stored blood samples from U.S. Air Force personnel who conducted aerial herbicide spray missions of Agent Orange during the Vietnam war found a more than 2-fold increased risk of the precursor to multiple myeloma known as monoclonal gammopathy of undetermined significance (MGUS), according to an article published online by JAMA Oncology.

Monoclonal antibodies are generated by clones of a type of white blood cell that have been fused to myeloma (cancer) cells to form fast - growing «hybridomas.»

The scientists discovered that dinaciclib, by interfering with UPR activation, caused multiple myeloma and myeloid leukemia cells to initiate a form of cell suicide known as apoptosis when exposed to agents that induced ER stress.

After being infused back into patients» bodies, these newly built cells both multiply and seek out a peptide expressed by the antigens NY - ESO - 1 and LAGE - 1 found in multiple myeloma cancer cells.

In examining these remaining myeloma cells, the Yale team discovered a previously unidentified biologic pathway induced by the immune modulating drugs that enabled the residual cancer cells to survive and proliferate.

Antibodies only bind to target cells Peptide antibodies developed by Kwak and co-discoverer, Hong Qin, Ph.D., assistant professor of Lymphoma / Myeloma, wipe out MDSCs in the blood, spleen and tumor cells of mice without binding to other white blood cells or dendritic cells involved in immune response.

The discovery was made by developing a mouse model of the disease that enabled researchers to track which of 15 genetic groups — or subclones — of myeloma cells spread beyond their initial site in the animals» hind legs.

A multiple myeloma patient whose cancer had stopped responding after nine different treatment regimens experienced a complete remission after receiving an investigational personalized cellular therapy known as CTL019 developed by a team at the University of Pennsylvania.

The team designed a different approach to study the therapy in myeloma, adding in an infusion of the patient's own stem cells along with their lymphodepleting chemotherapy (melphalan), followed by CTL019 infusion about two weeks later.

Although it is among the most highly metastatic of all cancers, multiple myeloma is driven to spread by only a subset of the myeloma cells within a patient's body, researchers at Dana - Farber Cancer Institute have found in a study presented at the annual meeting of the American Society of Hematology (ASH).

«Updated criteria for diagnosing multiple myeloma published by international research group.»

A new study by researchers at The Ohio State University Comprehensive Cancer Center — Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC — James) provides evidence that genetically modifying immune cells might effectively treat multiple myeloma, a disease that remains incurable and will account for an estimated 24,000 new cases and 11,100 deaths in 2014

Dr. Rajkumar said multiple myeloma is always preceded sequentially by two asymptomatic conditions, monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM).

By attaching to the myeloma cells, it marks them for destruction, and by attaching to NK cells, it primes the immune cells to search for and attack the myeloma celBy attaching to the myeloma cells, it marks them for destruction, and by attaching to NK cells, it primes the immune cells to search for and attack the myeloma celby attaching to NK cells, it primes the immune cells to search for and attack the myeloma cells

Multiple myeloma patients got some good news on November 16 — the immunotherapy daratumumab (Darzalex ®) was given approval by the FDA for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy.

The laboratory is interested in mechanisms by which interactions between neutrophils and multiple myeloma cells promote disease progression and chemoresistance.

Multiple myeloma preferentially localizes in the bone marrow where the majority of surrounding cells are represented by mature and immature neutrophils.

Plerixafor has been approved by the FDA as the first small - molecule CXCR4 antagonist for use in combination with granulocyte - colony stimulating factor (GCSF) to mobilize hematopoietic stem cells to the bloodstream for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma and multiple myeloma.

Recent past honorees include Julian Adams of Infinity Pharmaceuticals, Alfred Goldberg of Harvard Medical School and Kenneth Anderson and Paul Richardson, both of Dana - Farber Cancer Institute, for the development of bortezomib, a drug that has altered the lives of hundreds of thousands of people with multiple myeloma; Alain Carpentier of Hôpital Européen Georges Pompidou in Paris and Robert S. Langer of MIT for innovations in bioengineering; and the work of Harald zur Hausen and Lutz Gissmann of the German Cancer Research Center on human papillomavirus (HPV) and cancer of the cervix, which was recognized by the WAFP prior to their receiving the Nobel Prize.

This enhances the immune response through multiple mechanisms: by attaching to the myeloma cells, it marks them for destruction, and by attaching to the NK cells, it primes the immune cells to search for and attack the myeloma cells.

The diagnosis of multiple myeloma is made by the presence of elevated abnormal plasma cells in the bone marrow.

Heidi Simmons decided to focus on cell therapy for treatment of blood cancers like leukemia, lymphoma and myeloma, where healthy cells are infused into patients to replenish those damaged by cancer.

«The surprising result was embodied by checkpoint expression in extramedullary myeloma showing that these lesions are able to reproduce their environment out of the bone,» said study co-author Alba Grifoni, PhD, from the Division of Vaccine Discovery at La Jolla Institute for Allergy and Immunology in La Jolla, California.

Pyrvinium pamoate inhibits proliferation of myeloma / erythro - leukemia cells by suppressing mitochondrial respiratory complex I and STAT3.

Supportive care is given to treat problems caused by multiple myeloma and other plasma cell neoplasms.

Signs and symptoms may be caused by multiple myeloma or other conditions.

A study led by Helena Jernberg Wiklund, Uppsala University / SciLifeLab, shows how the protein EZH2 affects the development of multiple myeloma, and that inhibition of EZH2 could be used as a new strategy to treat the disease.

Follin - Arbelet V, Torgersen ML, Naderi EH, Misund K, Sundan A, Blomhoff HK Death of multiple myeloma cells induced by cAMP - signaling involves downregulation of Mcl - 1 via the JAK / STAT pathway Cancer Lett (in press) PubMed 23454584